22.05.2013 - Danish Novo A/S has strengthened its pipeline of anti-infectives against multidrug resistant bugs by acquiring Norwegian Xellia Pharmaceuticals.
The holding company of the Danish insulin producer Novo Nordisk purchased all shares of Xellia from 3i and other shareholders. As a consequence of the US$700m transaction, Xellia’s headquarters will move from Oslo to Copenhagen. The API manufacturer, which was spun-out from Alpharma Inc in 2008, is the leading supplier of the last resort antibiotic Vancomycin, the Gram-negative killing drug Colistimethate Sodium (CMS), antifungal medicines and corticosteroids.
Xellia has built a pipeline of generic anti-infective treatments, and has extensive semi-synthetic and biological manufacturing know-how, including strain development and manufacturing. Novo's investment will allow Xellia to boost its R&D and to improve its market reach.
16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.
10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.
05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.
03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.